240 likes | 404 Views
Sustaining Priority Research for Neglected Tropical Diseases. Rob Ridley Director, TDR. TDR 'twin' Mission. To undertake research, development and evaluation of new and improved tools and interventions to fight major tropical diseases
E N D
Sustaining Priority Research for Neglected Tropical Diseases Rob Ridley Director, TDR
TDR 'twin' Mission • To undertake research, development and evaluation of new and improved tools and interventions to fight major tropical diseases • To strengthen research capabilities in countries where these diseases are endemic • enhanced stakeholdership / ownership of research
A vicious cycle DISEASE POVERTY
Many 'Neglected Diseases' Mortality Estimates for 2002 (World Health Report 2004) • Infectious and Parasitic diseases 10 904 (000) • HIV/AIDS 2 777 ¨ • Diarrhoeal diseases 1 798 ¨ • Tuberculosis 1 566 ¨ • Malaria 1 272 ¨ • Childhood diseases 1 124 ¨ • STI (excluding HIV) 180 ¨ • Meningitis 173 ¨ • (Other) Tropical Diseases 129 ¨ • Hepatitis B 103 ¨ • Hepatitis C 54 ¨ • Dengue 19 ¨ • Japanese encephalitis 14 ¨ • Intestinal nematode 12 ¨ • Leprosy 6 ¨
Tropical Disease Burden Poverty Poverty Control/ Elimination Of Tropical Diseases reduction Strategy ??
Innovation to Impact Grand Challenges NIH, Trust, Research councils etc.
Need to sustain and increase basic science funding
Examples of public private partnerships that have delivered new tools
Innovation to Impact – product development EDCTP MMV Microbicides DNDi GATB IAVI FIND MVI
8 new drugs anticipated by 2010 Proposed fund of $200M per year to complement PPP's Product Development Activities Need Sustaining
Examples of TDR – mediated evaluation and implementation research • Onchocerciasis • Ivermectin and Community Directed Treatment • Malaria • Home management of malaria strategies • Visceral Leishmaniasis • Tools in place for 'elimination' programmes A critical area for future funding given increase of tools in pipeline
Example in progress Visceral Leishmaniasis New tools stimulate India / Nepal / Bangladesh to sign MoU for elimination of VL by 2015 • Local ownership of research critical • Recognition of significance of social, economic and behavioural research • Research must be embedded in and owned by countries and integrated into health systems • Inter-country coordination facilitated by WHO / SEARO / TDR • Requires a co-ordinated approach by partners for maximal impact
Challenges No. 1 • Maintained funding for basic science, continued innovation and PPP product development • Better balance for more neglected diseases • Better management of translation research • Enhanced Evaluation and Implementation Research for all diseases • Enhanced coordination and interaction between initiatives, funding agencies, governments and regional bodies • Role for international agencies
Challenges No. 2 • Need capacity building coupled to capacity utilisation • Need to enhance country participation, 'stakeholdership' and ownership of research • Need to 'embed' the output of research activities within the institutions of developing countries • Need to enhance capabilities of developing countries to engage in 'innovation' as well as implementation
Use-inspired Research